Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-09-17 | technetium Tc 99m tilmanocept | Navidea Biopharmaceuticals (USA) | sentinel lymph node detection in patients with head and neck cancer |
Granting of the orphan status in the US |
2015-01-16 | oral exenatide | Oramed (Israel) | type 2 diabetes |
Granting of a patent |
2015-01-22 | eliglustat (analog of D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol) | Genzyme (USA - MA), a Sanofi company (France) | Gaucher disease type 1 |
Granting of a Market Authorisation in the EU |
2016-02-17 | delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant | GW Pharmaceuticals (UK) | glioma |
Granting of the orphan status in the EU |
2013-12-15 | Medigene (Germany) | |||
2013-12-17 | belinostat | Topotarget (Denmark), now Onxeo (France) - Spectrum Pharmaceuticals (USA - CA) | peripheral T-cell lymphoma (PTCL) | Granting of a Market Authorisation in the US |
2013-12-19 | anti-inhibitor coagulant complex | Baxter (USA - IL) | routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors |
Granting of a Market Authorisation in the US |
2013-12-23 | travoprost | Alcon (Novartis - Switzerland) | decrease of elevated intraocular pressure in adult patients with ocular hypertension or open angle glaucoma | |
2013-12-23 | apixaban | BMS (USA - NY) Pfizer (USA - NY) | treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE |
Granting of a Market Authorisation in the US |
2015-06-22 | cangrelor | The Medicines Company (USA - NJ) | reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention |
Granting of a Market Authorisation in the US |
2015-04-22 | liraglutide 3 mg | Novo Nordisk (Denmark) | adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities |
Product launch |
2013-12-23 | brimonidine tartrate | Galderma (Switzerland) | symptomatic treatment of facial erythema of rosacea in adults | |
2014-03-20 | florbetaben 18F | Piramal Imaging (Germany - India) | Positron Emission Tomography (PET) imaging of Beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment |
Granting of a Market Authorisation in the US |
2016-08-25 | tocilizumab | Roche (Switzerland) |
|
Submission of an sNDA |
2014-08-22 | flutemetamol F 18 injection | GE Healthcare (USA) | diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer\'s disease (AD) and dementia |
Granting of a Market Authorisation in the EU |
2017-03-23 | eslicarbazepine acetate | Sunovion Pharmaceuticals, US subsidiary of Dainippon Sumitomo Pharma (USA - Japan) Bial (Portugal) | seizures associated with epilepsy, partial-onset seizures | Positive opinion for the granting of a Market Authorisation in the EU |
2014-11-20 | ospemifene | Shionogi (Japan) | treatment of women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause |
Positive opinion for the granting of a Market Authorisation in the EU |
2014-01-05 | recombinant human nerve growth factor | Dompé (Italy) | retinitis pigmentosa | Granting of the orphan status in the US |
2015-01-19 | nintedanib | Boehringer Ingelheim (Germany) | idiopathic pulmonary fibrosis | Granting of a Market Authorisation in the EU |
2015-11-18 | Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA | Lysogene (France) | mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+